Vancomycin-Associated Nephrotoxicity: The Obesity Factor

被引:18
|
作者
Davies, Stephen W. [1 ]
Efird, Jimmy T. [2 ]
Guidry, Christopher A. [1 ]
Dietch, Zachary C. [1 ]
Willis, Rhett N. [1 ]
Shah, Puja M. [1 ]
Hennessy, Sara A. [1 ]
Sawyer, Robert G. [1 ]
机构
[1] Univ Virginia, Sch Med, Dept Gen Surg, Charlottesville, VA 22908 USA
[2] E Carolina Univ, Biostat Unit, Brody Sch Med, Ctr Hlth Dispar, Greenville, NC USA
基金
美国国家卫生研究院;
关键词
RETROSPECTIVE ANALYSIS; IMPACT; PHARMACOKINETICS; DYSLIPIDEMIA; INFECTIONS; OVERWEIGHT; TOXICITY; OUTCOMES; DOSAGE;
D O I
10.1089/sur.2014.198
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Current recommendations suggest that vancomycin dosing utilize actual rather than ideal body weight in obese patients. Thus, obese patients may be at greater risk for nephrotoxicity. The purpose of this study was to compare the incidence of nephrotoxicity in vancomycin-treated obese and lean patients at our institution, where unadjusted, actual body weight-based dosing (capped at 2g per dose twice daily) is used. We expected obese patients to experience a greater incidence of nephrotoxicity than lean patients. Methods: This study examined a retrospective cohort of patients treated with vancomycin for gram-positive or mixed infections in our facility from 2005-2009 who were not receiving hemodialysis at the time of admission. Patients were stratified by body mass index (BMI; obese 30kg/m(2) vs. lean <30kg/m(2)). Relative risk (RR), 95% confidence intervals (CIs), and p values were computed using a generalized estimating equation to accommodate a correlated data structure corresponding to multiple episodes of infection per individual. Multivariable analysis was performed. Results: A total of 530 patients (207 obese; 323 lean) with 1,007 episodes of infection were treated with vancomycin. Patient demographics, co-morbidities, sites of infection, and infecting organisms were similar in the two groups. Female gender (p=0.042), diabetes mellitus (DM) (p=0.018), and hypertension (HTN) (p=0.0009) were more often associated with obesity, whereas allografts (p=0.022) and peripheral vascular disease (p=0.036) were more often present in lean patients. The Acute Physiology and Chronic Health Evaluation II score >21 was the only variable associated with nephrotoxicity (p=0.039). After adjusting for statistically significant variables, obesity was found not to be associated with a greater risk of nephrotoxicity (RR=0.98; 95% CI=0.93-1.04; p=0.59). Conclusion: No difference in nephrotoxicity was observed between lean and obese patients treated with vancomycin at our institution.
引用
收藏
页码:684 / 693
页数:10
相关论文
共 50 条
  • [1] Vancomycin-Associated Tubular Casts and Vancomycin Nephrotoxicity
    Tantranont, Ngoentra
    Luque, Yosu
    Hsiao, Mary
    Haute, Claire
    Gaber, Lillian
    Barrios, Roberto
    Adrogue, Horacio E.
    Truong, Luan D.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2021, 6 (07): : 1912 - 1922
  • [2] Incidence and Predictors of Vancomycin-Associated Nephrotoxicity
    Moh'd, Hamzah
    Kheir, Fayez
    Kong, Lan
    Du, Ping
    Farag, Hosam
    Mohamad, Ahmad
    Zurlo, John J.
    [J]. SOUTHERN MEDICAL JOURNAL, 2014, 107 (06) : 383 - 388
  • [3] Commentary on "Incidence and Predictors of Vancomycin-Associated Nephrotoxicity''
    Bookstaver, P. Brandon
    Justo, Julie Ann
    [J]. SOUTHERN MEDICAL JOURNAL, 2014, 107 (06) : 389 - 390
  • [4] Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?
    Hazlewood, Kathleen A.
    Brouse, Sara D.
    Pitcher, William D.
    Hall, Ronald G.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2010, 123 (02): : 182.e1 - 182.e7
  • [5] Vancomycin-Associated Nephrotoxicity: Unintentional Consequences of a Loading Dose? Reply
    Hanrahan, Timothy P.
    Harlow, Georgina
    Dulhunty, Joel M.
    Lipman, Jeffrey
    Whitehouse, Tony
    Roberts, Jason A.
    [J]. CRITICAL CARE MEDICINE, 2015, 43 (05) : E154 - E155
  • [6] Prevalence of Risk Factors for Vancomycin-Associated Nephrotoxicity in a National Cohort
    Luther, Megan K.
    LaPlante, Kerry L.
    Caffrey, Aisling R.
    Dosa, David
    Lodise, Thomas P.
    Morrill, Haley J.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 80 - 80
  • [7] The Influence of a Therapeutic Drug Monitoring Service on Vancomycin-Associated Nephrotoxicity
    Yang, Jennifer J.
    Brett, Jonathan
    Sordo, Anna
    Reuter, Stephanie E.
    Stocker, Sophie L.
    Day, Richard O.
    Roberts, Darren M.
    Carland, Jane E.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (01): : 19 - 29
  • [8] Vancomycin-Associated Nephrotoxicity in the Critically III: A Retrospective Multivariate Regression Analysis
    Hanrahan, Timothy P.
    Harlow, Georgina
    Hutchinson, James
    Dulhunty, Joel M.
    Lipman, Jeffrey
    Whitehouse, Tony
    Roberts, Jason A.
    [J]. CRITICAL CARE MEDICINE, 2014, 42 (12) : 2527 - 2536
  • [9] Vancomycin-Associated Nephrotoxicity In The Intensive Care Unit (ICU) Is Not Associated With Increased Mortality
    Scerpella, E. G.
    Welch, V. L.
    Haque, N. Z.
    Kett, D. H.
    Peyrani, P.
    Ford, K. D.
    Ramirez, J. A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [10] Relationship between vancomycin-associated nephrotoxicity and the number of combined nephrotoxic agents
    Ueki, T.
    Sanematsu, E.
    Furuya, Y.
    Shinohara, Y.
    Murakami, Y.
    Miyazaki, A.
    Sakamoto, Y.
    Nakashima, M. N.
    Nakashima, M.
    [J]. PHARMAZIE, 2020, 75 (06): : 279 - 283